Lilly gets back in infectious disease, via three M&A deals
Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8bn.
Arthrosi drug trial in gout delivers for new owner Sobi
Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad.
Datroway is first TROP2 drug for frontline breast cancer
AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.
Newel Health, Gerresheimer team up to help pharma embrace di...
Newel Health and Gerresheimer ally to help pharma firms embed digital endpoints, real-world data, and AI into clinical testing and commercialisation.
Gilead claims first FDA nod for a hepatitis D therapy
At its second attempt, Gilead has won FDA approval for chronic hepatitis D virus drug Hepcludex, four years after it was cleared in the EU.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Inizio Launches Intelligent Congress to Turn Event Investmen...
Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes
6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery